| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476268 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Sep, 2029
(5 years from now) | |
| US8227462 | NOVARTIS | Pyrrolidine-1,2-dicarboxamide derivatives |
Apr, 2033
(9 years from now) | |
Vijoice is owned by Novartis.
Vijoice contains Alpelisib.
Vijoice has a total of 2 drug patents out of which 0 drug patents have expired.
Vijoice was authorised for market use on 05 April, 2022.
Vijoice is available in tablet;oral dosage forms.
Drug patent challenges can be filed against Vijoice from 25 May, 2023.
The generics of Vijoice are possible to be released after 29 April, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 24, 2024 |
| Orphan Drug Exclusivity(ODE-396) | Apr 05, 2029 |
Drugs and Companies using ALPELISIB ingredient
NCE-1 date: 25 May, 2023
Market Authorisation Date: 05 April, 2022
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
VIJOICE family patents
